Hemostemix Confirms OTCQB Listing
Calgary, Alberta--(Newsfile Corp. - October 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it is now up-listed to trade on the OTCQB under symbol HMTXF. The common shares of Hemostemix will continue to trade on the Frankfurt Stock Exchange under the symbol "2VFO" and trade on the TSX Venture Exchange under the symbol "HEM". ABOUT OTCQB The OTCQB is recognized by the SEC as an established public market. As a verified...
2021-10-28 9:29 AM EDT
Hemostemix Confirms OTCQB Application is Filed
Calgary, Alberta--(Newsfile Corp. - October 19, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it filed with the compliance department of OTCQB all documentation required to up-list the Company's common shares on the OTCQB. The Company's application is under review. The common shares of Hemostemix will continue to trade on the Borse Frankfurt under the symbol "2VFO" and trade on the TSX Venture Exchange under the symbol...
2021-10-19 12:06 PM EDT
Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
Calgary, Alberta--(Newsfile Corp. - October 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer. Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of...
2021-10-14 9:15 AM EDT
Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain
Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the second in its series of video interviews with ACP-01 recipients taped during August of 2021. With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this one-minute segment Peter recounts how his chest pain dissipated one...
2021-10-04 2:05 PM EDT
Hemostemix Announces Closing of First Tranche of Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - September 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed a first tranche of its previously announced non-brokered private placement of units ("Units") announced on September 8, 2021, for gross proceeds of $373,500 (the "Offering"). The Offering consisted of the issuance of an aggregate of 1,494,000 Units at a price of $0.25 per Unit. Each Unit consists of one common share in the capital of the...
2021-09-21 9:21 AM EDT
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Calgary, Alberta--(Newsfile Corp. - September 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the first of a series of video interviews with ACP-01 recipient-patients taped during August of 2021. Treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, chronic obstructive pulmonary disease and vascular dementia, each recipient of the ACP-01 treatment recounts in full detail their return to a quality of...
2021-09-14 9:10 AM EDT
Hemostemix Announces Five Million Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - September 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement for gross proceeds of up to $1,250,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 5,000,000 units ("Units") at a price of $0.25 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant...
2021-09-08 4:54 PM EDT
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Calgary, Alberta--(Newsfile Corp. - July 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to provide an update on the Phase II Clinical Trial, an update of a decision including a cost award from the Ninth Judicial Circuit Court of Orange County, Florida, and the Annual General Meeting ("AGM") results. Hemostemix is continuing to complete the groundwork necessary to derive its Phase II Clinical Trial analyses. The process to rescue...
2021-07-06 6:22 PM EDT
Hemostemix Announces Warrant Repricing and Extension
Calgary, Alberta--(Newsfile Corp. - July 5, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce, subject to TSX Venture Exchange Approval, that it has extended for two years and repriced to $0.55 from $1, subject to the accelerator provisions stated below on all repriced warrants, 1,332,500 Warrants expiring July 9, 2021; extended 918,450 Warrants expiring November 24, 2021 of which 510,295 Warrants are repriced to $0.55...
2021-07-05 6:25 PM EDT
Peter Lacey Increases His Investment in Hemostemix Inc.
Calgary, Alberta--(Newsfile Corp. - June 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") announced today that, further to its June 11, 2021 news release and pursuant to the closing of the offering of debenture units of the Company ("Debenture Units"), Peter Lacey, a director and Chair of Hemostemix, acquired the 2,500 Debenture Units. Each Debenture Unit consisted of a $1,000 principal amount debenture (each, a "Debenture") and 2,500 common...
2021-06-21 10:01 PM EDT
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 11, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it closed its previously announced $2,500,000 convertible debenture order from a director of the Company for Debenture Units priced at $1,000 per Unit as detailed below. CLINICAL TRIAL UPDATE Hemostemix has obtained a new copy of its clinical trial data base from a former service provider who originally activated the clinical...
2021-06-11 8:10 AM EDT
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record
Calgary, Alberta--(Newsfile Corp. - May 31, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE:2VF0) ("Hemostemix" or the "Company") reminds shareholders that due to COVID-19, its Annual and Special Meeting will be held by Zoom only. Shareholders are invited to the following scheduled Zoom meeting, per the information circular mailed to all shareholders of record. Topic: The Annual and Special Meeting of the Shareholders of Hemostemix Inc. Time: May 31, 2021 11:00 AM MST (Calgary)...
2021-05-31 10:38 AM EDT
Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update
Calgary, Alberta--(Newsfile Corp. - May 29, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce that it has obtained preliminary approval from the TSX Venture Exchange to close a $2,500,000 convertible debenture order from a director for Debenture Units priced at $0.40 per Unit as detailed below. On May 28, 2021, Hemostemix filed its Financial Statements and Management Discussion and Analysis for the period ending March 31,...
2021-05-29 3:56 PM EDT
Hemostemix to Present at the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - May 25, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce that it will present live at the Emerging Growth Conference on May 26, 2021 from 3:30 - 4:00 ET and it invites shareholders, individual and institutional investors, as well as advisors and analysts to attend its real-time, interactive presentation. Attendees are invited to register here to ensure you are able to attend the...
2021-05-25 11:39 AM EDT
Hemostemix Announces Closing of Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - May 10, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") announced on April 9, 2021, for gross proceeds of $440,031.90 (the "Offering"). The Offering consisted of the issuance of an aggregate of 1,257,234 Units at a price of $0.35 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and...
2021-05-10 10:16 PM EDT
Hemostemix Announces Warrant Repricing and Extension
Calgary, Alberta--(Newsfile Corp. - May 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading...
2021-05-06 8:38 PM EDT
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
Calgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up completed in April, the Company is now focusing its efforts on completing the key areas of the trial including, but not limited to, data entry, source document verification, data base query management and validation as more fully described below, biostatistical analyses and final reporting...
2021-04-30 10:22 PM EDT
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 26, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Company") announces that, further to its April 9, 2021 news release announcing its Unit Offering, it has increased the aggregate gross proceeds of its Unit Offering to $1,050,000, reduced the Unit price to $0.35 per Unit, and reduced the exercise price of the Warrants to $0.40 per Common Share. In addition, further to its April 9, 2021 news release...
2021-04-26 9:00 AM EDT
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the...
2021-04-23 3:00 PM EDT
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
Calgary, Alberta--(Newsfile Corp. - April 9, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has secured a $2,500,000 lead order from a director for Debenture Units, and intends to raise gross proceeds of up to $4,000,000 from the non-brokered Offerings of Units and Debenture Units, all as discussed below. The Company is progressing with completion of the phase II clinical trial data entry, source document...
2021-04-09 8:56 PM EDT